A Study of YM178 in Patients With Symptomatic Overactive Bladder

A Randomized, Double-blind, Parallel-group, Placebo-controlled Study in Patients With Symptomatic Overactive Bladder

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00527033

Enrollment

842

Registered

2007-09-10

Start date

2007-09-11

Completion date

2008-04-03

Last updated

2024-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Bladder, Overactive

Keywords

YM178, Urinary Bladder, Overactive

Brief summary

Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo

Detailed description

To investigate the dose-response relationship of YM178 in terms of efficacy, safety and tolerability, and also the superiority of YM178 over placebo.

Interventions

DRUGYM178

Oral

DRUGPlacebo

Oral

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients over 20 years suffering from overactive bladder

Exclusion criteria

* Pregnant and breastfeeding women * Any clinically significant abnormal conditions which in the opinion of the investigator makes the patient unsuitable for the study

Design outcomes

Primary

Measure	Time frame
Overactive bladder symptoms	12 weeks

Secondary

Measure	Time frame
Overactive bladder symptoms (QOL)	12 weeks

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026